FilingReader Intelligence

Zhejiang Medicine boosts 2024 profit, proposes cash dividend

April 23, 2025 at 05:38 PM UTCBy FilingReader AI

Zhejiang Medicine (SSE:600216) has announced a robust financial performance for 2024, accompanied by a proposal to distribute CNY355.8 million in cash dividends. The company's board has approved a plan to allocate CNY0.37 per share to all shareholders, contingent on shareholder approval at the upcoming 2024 Annual General Meeting.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

SSE:600216Shanghai Stock Exchange
Pharmaceuticals

News Alerts

Get instant email alerts when Zhejiang Medicine publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →